The Autoantibody Pathway

When immune system B cells, known as plasmablasts and plasma cells, become autoreactive and the mechanisms that normally eliminate or suppress these cells fail, autoantibodies are created. In autoimmune disease, these autoantibodies become pathogenic and attack one’s body as opposed to foreign pathogens, causing inflammation. A number of autoimmune diseases, including NMOSD, myasthenia gravis and IgG4-related diseases, as well as conditions like kidney transplant rejection, are associated with the autoantibody pathway.

Inebilizumab, our lead product candidate, is designed to bind to CD19, a cell surface molecule broadly expressed on B cells, initiating B cell depletion. This depletion stops autoreactive B cells from differentiating into antibody-secreting plasmablasts and plasma cells, which decreases the production of pathogenic autoantibodies, lessening the autoimmune response.